Shionogi company profile
Company profile
Shionogi has 6,223 employees and is headquartered in Kita, Japan.
Shionogi & Co., Ltd. sells its pharmaceuticals, diagnostic reagents and medical devices in Japan and internationally. Its business covers research, development, manufacture and distribution of these products, alongside a consumer healthcare business. The company also develops mucosal vaccines, manufactures investigational drugs, and offers contract research and testing services for experimental research, agricultural production materials and pharmaceutical engineering, as well as IT and marketing support for healthcare customers.
In the fiscal year ended March 2026, revenue rose 14.0% to 499.7 billion yen, and net income reached 205.2 billion yen. The company was founded in 1878, changed its name from Shionogi Shoten Co., Ltd. in 1943, employs 6,223 people and is headquartered in Kita, Japan.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Japan
- Headquarters
- Park Tower, 530-0011, Kita
- Employees
- 6,223
- Chief executive
- Isao Teshirogi
- Founded
- 1878
- Fiscal year
- April - March
- Listing
- 4507 · TSE
- Indices
- Nikkei 225
- Currency
- JPY
- ISIN
- JP3347200002
- Website
- shionogi.com
Shionogi and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Shionogi4507 | Japan | $16.75B | 6,223 | 31.6% | 11.2 |
| PharmaEssentia6446 | Taiwan | $15.94B | 131 | 38.4% | 74.1 |
| Yunnan Baiyao Group000538 | China | $15.07B | 9,286 | 11.2% | 19.4 |
| Torrent PharmaceuticalsTORNTPHARM | India | $19.25B | 18,258 | 22.2% | 79.2 |
| Laurus LabsLAURUSLABS | India | $14.13B | 7,059 | 24.1% | 97.8 |
| Zydus LifesciencesZYDUSLIFE | India | $12.92B | 29,980 | 17.2% | 28.7 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
